Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway
Autor: | Xiaoting Wei, Bixia Tang, Caili Li, Lin Wu, Lu Si, Xieqiao Yan, Bin Lian, Xinan Sheng, Zhihong Chi, Lili Mao, Xuan Wang, Yabin Cao, Jie Dai, Jun Guo, Yanxiang Zhang, Yan Kong, Zhonghui Qi, Li Zhou, Siming Li, Xue Bai, Chuanliang Cui |
---|---|
Rok vydání: | 2021 |
Předmět: |
Adult
Male 0301 basic medicine Oncology Cancer Research medicine.medical_specialty Skin Neoplasms Pyridines Antineoplastic Agents Neutropenia Palbociclib Piperazines 03 medical and health sciences 0302 clinical medicine Internal medicine Biomarkers Tumor medicine Humans Adverse effect Melanoma Aged Leukopenia biology Cyclin-dependent kinase 4 business.industry Cyclin-Dependent Kinase 4 Middle Aged Prognosis medicine.disease Survival Rate Clinical trial 030104 developmental biology 030220 oncology & carcinogenesis Mutation biology.protein Biomarker (medicine) Female medicine.symptom business Follow-Up Studies |
Zdroj: | European Journal of Cancer. 148:297-306 |
ISSN: | 0959-8049 |
Popis: | Background Genetic aberrations in the cyclin-dependent kinase (CDK)4 pathway occur in 82% of patients with acral melanoma (AM), which is the predominant subtype of melanoma in China. We aimed to evaluate the anti-tumour activity of palbociclib, a selective CDK4/6 inhibitor, in patients with advanced AM with CDK4 pathway gene aberrations. Methods In this phase II trial, patients with advanced AM with CDK4 or/and CCND1 gain or/and CDKN2A loss were treated with oral palbociclib (125 mg) on days 1–21 of a 28-day cycle. The primary end-point was overall response rate (ORR). Secondary end-points were progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs). Whole-exome sequencing and multiplex immunohistochemistry of the available formalin-fixed, paraffin-embedded samples of nine patients were analysed to explore the predictive biomarkers of palbociclib response. Results Fifteen patients were enrolled. Three (20.0%) patients achieved tumour shrinkage at 8 weeks, including one with confirmed partial response. At data cut-off date, treatment was ongoing for one patient. The median PFS was 2.2 mo (range: 1.5–13.3 mo; 95% confidence interval [CI]: 1.9–2.5), and the median OS was 9.5 mo (range: 2.6–14.1 mo, 95% CI: 5.7–13.4). Eight patients died due to disease progression. The most common TRAEs were leukopenia (87%; Grade III/IV, 27%), neutropenia (80%; grade III/IV, 27%), and fatigue (53%; grade III/IV, 7%). Significant JAK2 deletions and SH2B3 amplifications were observed in patients who did not achieve any clinical benefit (CB) with palbociclib treatment. MCM7 amplification or protein expression level was found to be associated with CB. Conclusions Palbociclib monotherapy demonstrated preliminary efficacy and an acceptable safety profile in advanced AM patients with CDK4 pathway aberrations. Patients with amplification or high protein levels of MCM7 were more prone to benefit from palbociclib. The JAK-STAT pathway might play a role in the mechanism of action of palbociclib in AM. Trial registration number NCT03454919 . The date of registration March 6, 2018. |
Databáze: | OpenAIRE |
Externí odkaz: |